News | July 27, 2025
Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Subscribe To Our Newsletter & Stay Updated
